

The following information is prepared for the convenience of Canadian Derivatives Clearing Corporation (CDCC) members and Bourse de Montréal Inc. (the Bourse) approved participants. This document is an unofficial summary of certain terms of the aforementioned adjustment. CDCC and the Bourse accept no responsibility for the accuracy or completeness of the summary. CDCC members and Bourse approved participants must ensure they have reviewed the documentation published by the Issuers involved in this corporate action.



## NOTICE TO MEMBERS

No. 2021 - 175

November 19, 2021

### FINAL CONTRACT ADJUSTMENT Trillium Therapeutics Inc. (TRIL) Plan of Arrangement

The Bourse and CDCC wish to inform you that Pfizer Inc. (NYSE: PFE) (“Pfizer” or the “Company”) and Trillium Therapeutics Inc. (TSX: TRIL; Nasdaq: TRIL) (“Trillium”) announced on November 17, 2021, the completion of their previously announced plan of arrangement.

Pursuant to the terms of the Plan of Arrangement, Trillium shareholders will receive US \$18.50 in cash in exchange for each Trillium common share.

The common shares of Trillium Therapeutics Inc. will be delisted from the Toronto Stock Exchange at the close of business on November 19, 2021.

#### **CDCC - Adjustment Details:**

Pursuant to the Terms of Adjustment provided in Section A-902 of the Rules of CDCC, all TRIL options will be adjusted as follows:

- **EFFECTIVE DATE:** November 22, 2021
- **OPTIONS SYMBOL:** TRIL will become TRIL1
- **NUMBER OF CONTRACTS:** Unchanged
- **MULTIPLIER:** 100
- **NEW DELIVERABLE PER CONTRACT:** A cash consideration of USD \$1850.00
- **STRIKE PRICES:** Unchanged
- **NEW CUSIP :** NOTACUSIP



- **POSITION AND EXERCISE LIMITS:** Position and exercise limits will remain unchanged at 250,000 contracts

CDCC will not adjust any outstanding escrow receipts.

**ACCELERATED EXPIRY**

Please note that on December 17, 2021, an acceleration of the expiration dates for all outstanding option series will be applied.

**Trillium Therapeutics Inc. (TRIL) – TRIL1**

Existing American-style Trillium Therapeutics Inc. options remain exercisable at the option of the holder prior to the accelerated expiration date (December 17, 2021). Exercised options will continue to settle in two business days.

**The Bourse - Adjustment Details:**

It is important to note that on the effective date mentioned above, all open orders on this option class **will not be automatically modified** to reflect the plan of arrangement and will therefore have to **be re-entered** into the Montreal Automated System (SAM) by the approved participants.

The existing series of TRIL options class will be transferred to the TRIL1 options class representing the new deliverable.

<b>Actual Class Symbol</b>	<b>New Class Symbol</b>
TRIL	TRIL1

Please note that only closing transactions will be permitted on the adjusted class. Actual series that do not have open interest will not be adjusted.

**PLEASE ENSURE THAT ALL CLIENTS WHO HAVE EITHER LONG OR SHORT POSITIONS IN THIS OPTION CLASS ARE ADVISED OF THIS NOTICE.**

For further information, please contact the Market Operations Department at (514) 871-7877. Clearing members may contact the CDCC Corporate Operations Department.

Anne Fiddes  
Vice President, Integrated Operations CDCC